Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Thymoma × NVP-BKM120 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 22 Neoplasm Metastasis 15 Carcinoma, Non-Small-Cell Lung 7 Glioblastoma 6 Colorectal Neoplasms 5 Triple Negative Breast Neoplasms 4 Recurrence 4 Ovarian Neoplasms 4 Lymphoma, Mantle-Cell 4 Lymphoma, Follicular 4 Endometrial Neoplasms 4 Brain Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 3 Prostatic Neoplasms 3 Pancreatic Neoplasms 3 Neoplasms 3 Lymphoma, Large B-Cell, Diffuse 3 Lung Neoplasms 3 Hereditary Sensory and Autonomic Neuropathies 3 Head and Neck Neoplasms 3 Solid Tumors 2 Melanoma 2 Lymphoma 2 Leukemia, Myeloid, Acute 2 Leukemia, Lymphocytic, Chronic, B-Cell 2 Esophageal Neoplasms 2 Waldenstrom Macroglobulinemia 1 Unspecified Adult Solid Tumor, Protocol Specific 1 Treatment for Metastatic or Locally Advanced Cervical Cancer 1 Tongue Neoplasms 1

Interventions

pembrolizumab 6 Radiotherapy 6 Cyclophosphamide 6 Cisplatin 6 Sunitinib 5 Carboplatin 5 Paclitaxel 4 Thymectomy 3 130-nm albumin-bound paclitaxel 3 selinexor 2 lenvatinib 2 Taxes 2 Robotic Surgical Procedures 2 Ramucirumab 2 Prednisone 2 Pemetrexed 2 Octreotide 2 Nivolumab 2 N,1,4,4-tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide 2 Methylprednisolone 2 Imatinib Mesylate 2 Etoposide 2 Erlotinib Hydrochloride 2 Drug Therapy 2 Doxorubicin 2 Chemoradiotherapy 2 Celecoxib 2 zimberelimab 1 vorolanib 1 saracatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02220855 2022-04-11

A Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas

Indiana University

Phase 2 Completed

14 enrolled 14 charts

Thymoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡